Ana Sampedro

Pamplona, NC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

New cases of δ-aminolevulinic acid dehydratase deficiency: Functional insights into gene variants using an innovative mouse liver model.

New cases of δ-aminolevulinic acid dehydratase deficiency: Functional insights into gene variants using an innovative mouse liver model.

Journal: Journal of internal medicine

Published: November 21, 2025

Oral lipoteichoic and lipoic acids improve insulin resistance and body composition in porphyria mice on a high-carbohydrate diet.

Oral lipoteichoic and lipoic acids improve insulin resistance and body composition in porphyria mice on a high-carbohydrate diet.

Journal: Journal of physiology and biochemistry

Published: May 22, 2025

Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates.

Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates.

Journal: Gut

Published: April 09, 2024

Nutritional Interventions with Bacillus coagulans Improved Glucose Metabolism and Hyperinsulinemia in Mice with Acute Intermittent Porphyria.

Nutritional Interventions with Bacillus coagulans Improved Glucose Metabolism and Hyperinsulinemia in Mice with Acute Intermittent Porphyria.

Journal: International journal of molecular sciences

Published: June 29, 2023

Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment.

Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment.

Journal: Life (Basel, Switzerland)

Published: October 20, 2022

Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases.

Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases.

Journal: International review of cell and molecular biology

Published: September 05, 2022

Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria.

Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria.

Journal: Science translational medicine

Published: January 12, 2022

High Prevalence of Insulin Resistance in Asymptomatic Patients with Acute Intermittent Porphyria and Liver-Targeted Insulin as a Novel Therapeutic Approach.

High Prevalence of Insulin Resistance in Asymptomatic Patients with Acute Intermittent Porphyria and Liver-Targeted Insulin as a Novel Therapeutic Approach.

Journal: Biomedicines

Published: January 19, 2021

mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks.

mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks.

Journal: Molecular therapy. Nucleic acids

Published: December 12, 2020

Brain ventricular enlargement in human and murine acute intermittent porphyria.

Brain ventricular enlargement in human and murine acute intermittent porphyria.

Journal: Human molecular genetics

Published: June 19, 2020

Computational disease model of phenobarbital-induced acute attacks in an acute intermittent porphyria mouse model.

Computational disease model of phenobarbital-induced acute attacks in an acute intermittent porphyria mouse model.

Journal: Molecular genetics and metabolism

Published: September 18, 2018

Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria.

Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria.

Journal: Human molecular genetics

Published: June 01, 2018

Showing 1-12 of 22

Last Updated: 09/26/2026